Tybourne Capital Management

Tybourne Capital Management is a global investment firm focusing on public and private equity markets, with offices in Hong Kong and San Francisco. It uses a fundamental approach to equity investing across public and private markets and pursues growth and expansion opportunities, serving a diverse set of investors including endowments, institutions, charitable organizations, family offices and business founders.

Lindsay Campbell

Managing Director, Investor Partnerships

Terrence Cheng

Managing Director

Catherine Cheung

COO and Managing Director

Stephanie Hu

Managing Director

Eashwar Krishnan

Managing Partner and Portfolio Manager

Masa Mochida

Managing Director

Alexander Wang

Principal

26 past transactions

Forte Biosciences

Post in 2024
Forte Biosciences is a biotechnology company specializing in dermatology. Its lead product, FB-401, is a topically applied live biotherapeutic developed with the National Institutes of Health and National Institute of Allergy and Infectious Diseases for treating inflammatory skin diseases.

SkyCell

Series D in 2024
SkyCell is a provider of temperature-controlled pharma containers designed to transport sensitive medicines. The containers integrate IoT sensors that feed data to a cloud platform, enabling real-time monitoring, intervention, and end-to-end shipment visibility. The product lineup includes models such as 2500C, 2500CRT, 1500C, 1500CRT, 770C, and 770CRT. The company combines hardware, software, and services to optimize the pharmaceutical cold chain, aiming to reduce temperature excursions and emissions. Its data-driven approach leverages a growing set of data points to predict and mitigate risk in air shipments, while supporting sustainability through reduced carbon dioxide emissions. Founded in 2013 and based in Zurich, SkyCell serves global pharma customers, focusing on safe, reliable transport of temperature-sensitive therapies.

Forte Biosciences

Post in 2023
Forte Biosciences is a biotechnology company specializing in dermatology. Its lead product, FB-401, is a topically applied live biotherapeutic developed with the National Institutes of Health and National Institute of Allergy and Infectious Diseases for treating inflammatory skin diseases.

Clove Dental

Series D in 2022
Clove Dental operates a network of multi-specialty dental clinics that provide a wide range of professional oral healthcare services. With over 350 clinics and a patient base exceeding 1 million each month, Clove Dental specializes in various treatments including endodontics, periodontics, orthodontics, prosthodontics, cosmetic dentistry, pediatric care, and oral and maxillofacial surgery. The company is committed to high standards of hygiene, clinic safety, and customer service, employing more than 800 dentists and utilizing advanced equipment and pain-management technologies to enhance patient experiences.

Asuene

Series B in 2022
Asuene provides renewable power retail services for local production and consumption and develops a carbon management platform that enables organizations to track, manage, and report greenhouse gas emissions. The platform integrates data from multiple sources using artificial intelligence to create strategies for reducing pollutants, improving environmental performance, complying with regulations, and advancing sustainability goals.

Acelyrin

Series C in 2022
Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Kopi Kenangan

Series C in 2021
Established in 2017, Kopi Kenangan operates as a grab-and-go coffee chain in Indonesia. It aims to tap into the growing demand for specialty coffee beverages in a market that is one of the world's largest coffee exporters but has relatively low consumption per capita.

Lunit

Venture Round in 2021
Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.

Acelyrin

Series B in 2021
Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

CADDi

Series B in 2021
CADDi is a Japan-based platform that combines online procurement for industrial products with an AI-powered data platform that digitizes and analyzes manufacturing drawings and procurement information. It tracks industrial products across the manufacturing supply chain and automates extraction of details from drawings and handwritten documents into searchable digital records. Through Realize DX, the platform integrates goods and software to streamline procurement, reduce expenses, and improve quality, cost, and delivery while enabling capacity expansion. The data platform provides procurement intelligence and supply chain data to help manufacturers consolidate insights and support sourcing decisions. CADDi is headquartered in Tokyo, Japan.

Zentera Therapeutics

Series B in 2021
Zentera Therapeutics is a biopharmaceutical company.

Amylyx Pharmaceuticals

Series C in 2021
Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Wugen

Series B in 2021
Wugen is a biotechnology company developing off-the-shelf cellular therapies for cancer. It engineers memory natural killer (NK) cell and CAR-T therapies derived from healthy donors to deliver ready-to-use, consistent treatments that reduce production time and broaden patient access. The therapies target hematologic cancers and solid tumors, including acute myeloid leukemia and various T-cell malignancies.

Paidy

Series D in 2021
Paidy is a Japanese fintech company that offers a cardless real-time payment network. It enables consumers to buy online without a credit card or pre-registration, optimizing for mobile and instant-checkout. Paidy's platform uses proprietary technology to score creditworthiness, underwrite transactions, and guarantee payment to merchants.

Momo

Series D in 2021
Momo is a FinTech startup that provides a mobile electronic wallet and payment application for iOS and Android devices, primarily serving customers in Vietnam. The platform facilitates nationwide cash transfers, bill payments for over 100 types of services, mobile phone recharges, and personal loan settlements. Additionally, Momo enables users to purchase various services, including software licenses, online gaming cards, and tickets for airlines and movies. The company collaborates with 24 domestic banks and international payment networks, ensuring secure and efficient financial transactions for its users. Momo aims to simplify the payment experience, making it effortless and safe for individuals to manage their financial activities.

Provivi

Series C in 2020
Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

LianBio

Venture Round in 2020
LianBio is a biopharmaceutical company founded in 2019, headquartered in Shanghai, China, with an additional office in Princeton, New Jersey. The company is dedicated to the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as addressing other unmet medical needs in Greater China and major Asian markets. LianBio focuses on in-licensing assets and collaborates with leading partners to enhance its pipeline, which includes clinically validated product candidates across various therapeutic areas such as cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory indications. The company aims to accelerate the availability of innovative medicines to improve patient outcomes through a science-driven approach.

Zentera Therapeutics

Series A in 2020
Zentera Therapeutics is a biopharmaceutical company.

Paidy

Series C in 2019
Paidy is a Japanese fintech company that offers a cardless real-time payment network. It enables consumers to buy online without a credit card or pre-registration, optimizing for mobile and instant-checkout. Paidy's platform uses proprietary technology to score creditworthiness, underwrite transactions, and guarantee payment to merchants.

Provivi

Series C in 2019
Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

CarDekho

Series C in 2019
CarDekho is a technology services company that delivers mobile application development, web design and development, offshore staffing, and testing and quality assurance solutions. It offers consulting and development for enterprise mobility, including iOS, Android, and cross‑platform applications, as well as web services such as responsive design, CMS, e‑commerce, and custom web applications. The firm provides offshore talent for designers, developers, and QA specialists, and offers comprehensive testing services covering automated, manual, functional, and integration testing. CarDekho builds applications across a wide range of sectors, including automotive, e‑learning, finance, social networking, travel, health, job placement, news, utilities, entertainment, lifestyle, e‑commerce, IT, communication, and publishing.

Bicycle Therapeutics

Series B in 2018
Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

FreeCharge

Series C in 2015
FreeCharge is an e-commerce platform based in Mumbai, Maharashtra, specializing in online recharges for prepaid mobile phones, postpaid services, DTH, and data cards in India. Founded in August 2010 by Kunal Shah, FreeCharge revolutionized the recharge process by offering shopping coupons from major retailers as an incentive, effectively making recharges cost-free for users. Initially, the platform partnered with brands like McDonald's and Barista, later expanding to include prominent retailers such as Café Coffee Day, Domino's Pizza, and Shoppers Stop. By November 2012, FreeCharge reported daily online recharge transactions worth INR 6 million, amounting to INR 2.19 billion annually. In addition to recharges, the platform also facilitates bill payments for services like electricity, gas, and telecommunication, allowing users to complete transactions quickly and efficiently across various channels. Recognized for its innovative approach, FreeCharge was named one of India's most promising technology startups in 2011.

CarDekho

Series B in 2015
CarDekho is a technology services company that delivers mobile application development, web design and development, offshore staffing, and testing and quality assurance solutions. It offers consulting and development for enterprise mobility, including iOS, Android, and cross‑platform applications, as well as web services such as responsive design, CMS, e‑commerce, and custom web applications. The firm provides offshore talent for designers, developers, and QA specialists, and offers comprehensive testing services covering automated, manual, functional, and integration testing. CarDekho builds applications across a wide range of sectors, including automotive, e‑learning, finance, social networking, travel, health, job placement, news, utilities, entertainment, lifestyle, e‑commerce, IT, communication, and publishing.

GirnarSoft

Series B in 2015
Founded in 2007, GirnarSoft is a leading mobile and web solutions development company based in India. With over 900 top engineers and management professionals, the company offers a wide range of services including product development, manual testing, automation, mobile application development, custom software development, and automotive portals.

Snapdeal

Series E in 2014
Snapdeal is India's largest online marketplace, launched in February 2010, that connects buyers and sellers across a wide range of product categories including mobile phones, electronics, apparel, cosmetics, and home goods. The platform is designed to create a reliable and frictionless commerce ecosystem, offering convenient delivery options even to remote areas. Snapdeal is notable for its competitive pricing, featuring daily deals and discounts that make various products accessible to consumers. It has established itself as a market leader in the retail space and is recognized for its significant presence in categories such as watches, sunglasses, and jewelry. With over 1,000 employees, Snapdeal fosters a vibrant work environment and continues to play a critical role in India's e-commerce landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.